Targeted drugs such as oxidative phosphorylation inhibitors like metformin (approved for diabetes) and epigenetic modifiers like venetoclax (BCL2 inhibitor, approved for chronic lymphocytic leukemia (CLL), AML) and S63845 (MCL1 inhibitor, experimental) may be combined with first-line chemotherapeutic drugs (cytarabine, idarubicin) to improve AML treatment efficacy. The gene discussed is MCL1; the disease is diabetes mellitus.